INTRODUCTION
Ataxia telangiectasia (A-T) is a highly pleiotropic autosomal recessive disorder that is caused by mutations in the ataxia telangiectasia mutated (ATM) gene, located on the long arm of chromosome 11 (q22 -23) (1 -4) . The ATM transcript is a 370 kDa protein belonging to a subgroup of kinases that share homologies with the catalytic domain of phosphatidylinositol 3-kinases. ATM is centrally involved in cell-cycle checkpoint control and DNA repair after DNA double strand breaks (DSBs) caused by ionizing radiation (IR) or oxidative damage (5) . In response to DNA damage, more than 900 regulated phosphorylation sites encompassing over 700 proteins recognized by ATM and ATR (ataxia telangiectasia and Rad3 related) have been identified so far (6) .
A-T patients suffer from progressive neurodegeneration, severe bronchial complications, cellular and humoral immunodeficiency, oxidative stress, elevated risk of malignancies and * To whom correspondence should be addressed at: Children's Hospital, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. Tel: +49 069630183611; Fax: +49 069630183349; Email: Julia.Pietzner@kgu.de hypersensitivity to radiotherapy (7 -11) . Many patients also exhibit somatic growth retardation and growth factor deficiency (12, 13) . Their survival probability for the 20 year survival rate is 53.4%, and death is caused predominantly by lung failure and cancer. The prognosis has not changed since 1954 (14) . At present, only symptomatic therapies are available and no cure for A-T exists.
Potential therapeutic approaches have been proposed based on knowledge of the molecular and cellular characteristics of A-T, including treatments with myo-inositol, the use of antioxidants or growth hormones supplementation (15) (16) (17) (18) (19) . A further promising preclinical approach is the mutation-targeted therapy that ameliorates the ATM gene function through the aminoglycoside-induced read through of premature termination codons and the use of antisense morpholino oligonucleotides (20) (21) (22) . As a proof of principle, these methodologies are promising; however, the safety and effectiveness of the compounds will need to be demonstrated in clinical trials.
Correction of ATM gene function by mutation-targeted therapies suggests that ATM activity has to be at least partially restored for therapeutic strategies to cure A-T. In this regard, bone marrow transplantation (BMT) may partly restore ATM function. BMT is already used as curative therapy for several malignancies and other genetic instability syndromes (23) (24) (25) . Bone marrow-derived cells (BMDCs) include stem cells with proliferating and multipotent capacities, which are known to differentiate into different cell types, including cells of the nervous system and lung epithelial cells, which is of special interest for a therapeutic approach to A-T (26) .
However, despite the curative potential offered by BMT, ablation of an A-T patient's bone marrow is fraught with difficulties related to the inherent hypersensitivity of A-T cells to IR, radiomimetics and DNA-damaging agents (27) . To address this issue, Bagley et al. showed that BMT restores immune system function and prevents lymphoma in Atm-deficient mice using a clinically relevant non-myeloablative host-conditioning regimen (28) . Moreover, patients with other instability syndromes such as Fanconi anemia and Nijmegen breakage syndrome (NBS) underwent successful BMTs using reduced-intensity conditioning regimens (23, 25) . Interestingly, NBS, which shares many clinical features with A-T, was effectively treated by BMT in five of six patients (29) . These data suggest that BMT is feasible when treating genomic instability syndromes with reduced-intensity conditioning regimens.
In this study, we systemically administered ATM-competent BMDCs that ubiquitously express an enhanced green fluorescent protein (GFP) to evaluate whether these cells can traffic to the most affected tissues, brain and lung and provide ATM function using Bagley's reduced conditioning regimen. We determined that BMDC migrated into the thymus, spleen and lung tissue of Atm-deficient mice, but did not cross the blood -brain barrier (BBB). BMT inhibited thymic lymphomas, normalized T-lymphocyte populations and improved growth and motor activity in the recipient animals.
RESULTS
Grafting of ATM-competent BMDCs into Atm-knockout mice results in a stable chimerism and functional ATM Atm-deficient mice recapitulate most of the phenotype of the human disorder A-T, including immunodeficiency with lymphopenia involving the CD4 and CD8 T lymphocyte populations, growth abnormalities and increased risk of lymphocytic malignancies. To investigate whether engrafted bone marrow cells are able to migrate into different tissues (e.g. thymus, spleen, brain and lung) and to determine how this migration affects the A-T phenotype, we used GFP-transfected ATM-competent donor bone marrow cells as an indicator of cell migration into different tissues of Atmdeficient mice after BMT (Fig. 1A) . To minimize strainspecific effects, we crossed GFP +/2 B5/E [B6Tg(ACTbEGF-P)1Osb/J] mice, which ubiquitously express GFP (b-actin -GFP), with the Atm +/2 129 awb mouse strain. Because of the highly elevated radiation sensitivity of Atm-deficient mice, we used an established non-myeloablative host-conditioning regimen (28) .
We intravenously injected 6 × 10 6 donor wild-type GFP
+
BMDCs into Atm-deficient mice. Flow cytometric analysis showed that 56% (+2.6) of these cells expressed the GFP protein resulting in an engraftment of 16.3% (+4.3) of GFP + donor cells into the bone marrow of the recipients 10 weeks after transplantation (Fig. 1B) . After FACS for GFP + cells, PCR results revealed that the transplanted donor cells are competent for the ATM gene (Fig. 1C) . In addition, we found ATM expression in the GFP-negative fraction indicating a GFP-negative ATM-competent population.
To assess the functionality of the GFP + bone marrow cells, we investigated their DNA DSB repair capacity using the g-H2AX assay. No differences in g-H2AX induction could be detected 3 h after irradiation with 2 Gy (Fig. 1D) . After 24 h, wild-type cells showed a significantly lower g-H2AX expression and therefore a higher repair capacity when compared with Atm-deficient cells (Atm +/+ GFP +/2 55.8 + 2.2, n ¼ 3; Atm 2/2 GFP +/2 64.0 + 2.3). GFP + cells from transplanted Atm-deficient mice were in the range of the wild-type cells (51.2 + 4.3), whereas GFP-negative cells were found within the range of Atm-deficient cells (64.7 + 2.32).
To characterize BMDCs of wild-type, Atm-deficient and transplanted mice, we analyzed the hematopoietic stem cell fraction (CD34 + ) and determined the total number of myelopoietic progenitor cells by a colony-forming cell (CFC) assay and lymphoid and erythroid progenitor cells by flow cytometry. The number of colony-forming units (CFU) of granulocyte, erythrocyte, monocyte/macrophage, megakaryocyte (CFU-GEMM), CFU-granulocyte (CFU-G) and CFU-macrophage (CFU-M) was lower in Atm-deficient and transplanted mice after 2 weeks of culture (Fig. 1E) . Lymphoid T-cell (CD3e + cells) and B-cell (B220 + cells) progenitor cells were significantly decreased in Atm-deficient when compared with wild-type Figure 1 . Grafting of ATM-competent BMDCs into Atm 2/2 mice (A) Review of the transplant procedure. B5/EGFP mice (b-actin-GFP) were crossed with the 129 SvEv background. Of these backcrossed mice, 6 × 10 6 unfractionated GFP + ATM-competent wild-type BMDCs were injected into ATM-deficient recipients who were conditioned with anti-CD4 and anti-CD8 monoclonal antibodies and cyclophosphamide. One hallmark of A-T is the loss of CD4 + and CD8 + lymphocytes in the peripheral blood. Therefore, we analyzed these T-cell populations during the host-conditioning regime and transplantation procedure, especially with regard to the engraftment of GFP + donor cells ( Fig. 2A) . In wild-type donor mice, the GFP expression was 62.5% (+9.6) in the CD4 + and 64.2% (+8.5) in the CD8 + cell population ( Fig. 2A and B Fig. 2A and D) . After non-myeloablative host-conditioning regime, Atm-deficient mice showed successful depletion of T-cells ( Fig. 2A) Fig. 2A and C) .
Chimerism is associated along with an extended lifespan in Atm-deficient mice A major symptom in A-T patients is the high risk of developing malignancies, which is also reflected in the Atm-deficient mouse model (30) . Atm-deficient mice die from thymomas by 3-5 months of age. We investigated the effects of different transplantation models by the identification of GFP + cells in the peripheral blood of the recipient mice after 3 months (Fig. 3A) . A strong GFP signal was seen in blood cells of Atm-deficient mice transplanted with wild-type BMDCs (27.3%, +3.8).
No GFP + cells were found in wild-type mice (Atm +/+ ) injected with bone marrow derived from either wild-type or Atm-deficient mice. In Atm-deficient mice transplanted with knockout bone marrow, 1.1% (+0.5) GFP + cells were detected.
Transplantation with ATM-competent bone marrow cells significantly increased the longevity of the animals. In fact, only 1 out of 13 mice died throughout the experimental period of 9 months (Fig. 3B) . In contrast, transplantation of Atm-deficient bone marrow cells into wild-type mice did not shorten the lifespan of the animals (Fig. 3C) . Interestingly, transplantation of Atm-deficient bone marrow cells into Atmdeficient mice significantly increased the longevity of these mice. The median survival was 179 days when compared with 126 days in untreated Atm-deficient mice (Fig. 3C) .
BMT improves the growth and motor activity of Atm-deficient mice Atm-deficient mice are smaller than their wild-type littermates and exhibit decreased weight gain, recapitulating the growth deficiency of the human A-T phenotype. To determine whether BMT improves growth and general behavior, we measured body weight and performed open-field testing of transplanted Atm-deficient mice, untreated Atm-deficient mice and wild-type mice. Before transplantation (2 months), Atm-deficient mice exhibited lower weights when compared with wild-type mice (Atm 2/2 11.0 g + 0.5; Atm +/+ 15.5 g + 0.
3) (Fig. 4A ). Three months after transplantation, the average weight of the transplanted group increased significantly (20.4 g + 1.0) when compared with untreated Atm-deficient mice (17.7 g + 0.7; and reached the weight of the wild-type mice (21.8 g + 0.8).
Testing of spontaneous locomotion activity was performed using a standard open-field activity system 3 months after transplantation (Fig. 4B) . We simultaneously gathered information on horizontal activity (movement in the arena) and vertical activity (rearing) for 5 min. Although horizontal activity tests showed no difference between the experimental groups, vertical activity testing demonstrated that untreated Atm-knockout mice reared significantly less often (0.2 interruptions, +0.3) when compared with wild-type mice (1.8 interruptions, +0.4) and that BMT significantly improved the motor activity of Atm-deficient mice (1.0, +0.6).
Transplanted BMDCs traffic into thymus and spleen leads to p53 phosphorylation
The loss of ATM is known to result in a defect T-cell development. Therefore, we examined the thymus and spleen of the transplanted Atm-deficient mice for GFP + BMDCs. + cell population. We next tested both tissues for the presence of ATMpositive cells and looked for ATM function in the spleen. PCR analysis from cells of the thymus and the spleen of the transplanted Atm-deficient mice showed a positive signal for the ATM gene in both tissues (Fig. 5C ).
For the functional investigation, we performed western blot analysis for the phosphorylation of the ATM target protein p53 (pp53) using mock-irradiated and 2 Gy irradiated splenocytes of wild-type, non-transplanted and 10 weeks transplanted Atmdeficient mice (Fig. 5D ). We found a pp53 signal in the spleen of the wild-type and the transplanted mice after irradiation, providing evidence for functional ATM. In contrast, no signal was detected in the spleen of the non-transplanted Atm-deficient mice.
Traffic of ATM-competent BMDCs into lung tissue
Pulmonary failure is the main cause of morbidity and mortality in A-T patients (Fig. 6A) . Three different factors are responsible for lung failure in A-T: (i) recurrent infections with bronchiectasis, (ii) interstitial lung disease/pulmonary fibrosis and (iii) lung disease associated with aspiration and neuromuscular deficits resulting in bulbar and spinal system impairment (31) . Mild lung inflammation is demonstrable in some of the Atm-deficient mice (Fig. 6A) . Chloracetate esterase staining revealed patchy areas of neutrophilic inflammation and alveolar septal thickening in Atm-deficient mice.
To determine whether BMDCs migrate into lung tissue, we measured the engraftment of GFP + cells using flow cytometry and fluorescence microscopy of lung tissue sections 6 weeks and 6 months after transplantation, respectively.
For fluorescence microscopy, slices were stained with 4 ′ ,6-diamidino-2-phenylindole (DAPI) and anti-CD45 Alexa568 as common leukocyte marker. Lung sections from the GFP +/2 control mice displayed co-localization of green and blue fluorescence in an overlay, clearly showing that the GFP + signal in the cells was not an artifact of bleed-through between the channels (data not shown). Tissue sections from transplanted Atm-deficient mice demonstrated the presence of GFP + cells 6 months after transplantation, whereas no GFP + cells could be detected in untreated Atm-deficient mice (Fig. 6C) . The overlay of the GFP channel and anti-CD45 Alexa568 staining showed three distinct cell populations: donor cells of . These results revealed that not all of the GFP + cells were of hematopoietic origin. In addition, the overlay showed co-localization of DAPI and GFP double-positive cells within the lung tissue and not only in blood vessels.
To further characterize these GFP + cells, we performed flow cytometric analysis of CD31 +
CD45
2 for cells of endothelial origin and EpCAM + (CD326) for epithelial cells. We found that 6.37% (+2.49) of the lung cells in the transplanted Atm-deficient mice were GFP + 6 weeks after BMT (Fig. 6D ). In the GFP + cell population, 14.63% (+3.69) were of CD31 +
2 origin and 26.58% (+4.54) positive for CD326, giving further evidence that not only cells of hematopoetic background migrate into the lung of the transplanted animals (Fig. 6E) .
We further performed PCR for the presence of wild-type ATM gene and found ATM DNA expression in the perfused lung tissue from Atm-deficient mice 6 months after transplantation (Fig. 6F) . Therefore, our results clearly demonstrate the migration of donor-derived ATM-competent cells into the lung tissue of Atm-deficient mice.
Evidence for GFP-competent donor cells in neural tissue
A-T patients suffer from ataxia that is predominantly caused by shrinkage of the cerebellum and loss of Purkinje cells (Fig. 7A) . Atm-deficient mice closely recapitulate the human phenotype of A-T, but they probably die before degeneration becomes evident. To test whether BMDCs are able to cross the BBB, we first examined neurologic tissue for GFP + cells by fluorescence microscopy. We found that no GFP + cells had migrated into the brain of the transplanted animals (data not shown). To exclude the possibility that only GFP-negative donor-derived cells migrated into the cerebellum or cerebrum, PCR for the ATM gene was performed. The PCR showed no ATM DNA expression in the cerebellum of the transplanted Atm-deficient mice, confirming that no donor-derived cells crossed the BBB of transplanted Atm-deficient mice (Fig. 7B) .
To further investigate whether the prolonged life span of the transplanted Atm-deficient is accompanied by degeneration of the cerebellum, we next looked for signs of changes in the brains of transplanted Atm-deficient mice. We performed MRI that allowed high-resolution visualization and comparison of the neural tracts. To determine whether there were any changes in the brain architecture of transplanted mice, the ratio between the widths of the encephalic section and (Fig. 7C) . Furthermore, no differences were found in the size index of the cerebellum between 5-month-old (i) untreated Atm-deficient mice, (ii) transplanted Atm-deficient mice and (iii) wild-type mice. In contrast, 6 months after transplantation (8-month-old mice), Atm-knockout mice (SI 1.04, +0.001) showed a significantly decreased size index when compared with wild-type mice (SI 1.09, +0.005). All untreated Atm-knockout mice died before they reached the age of 8 months. Differences in the size index were never observed for the cerebrum. Pathologic examination of cerebellar tissue using anticalbindin staining to detect functional Purkinje cells did not show any signs of morphologic differences between Atm-deficient mice and wild-type mice at the age of 5 months (data not shown). In contrast, at the age of 8 months, three of eight transplanted Atm-deficient mice exhibited lesions in the Purkinje cell layer when compared with wild-type mice using the same method (Fig. 7D) . We could not detect any differences in rotarod testing between the groups (data not shown).
DISCUSSION
A-T, like other genomic instability syndromes, is characterized by a defective DNA damage response that results in a multisystemic disorder phenotype (16, 32) . In addition, lymphoid tumor development involving chromosome translocations derived through errors in immune system gene rearrangement occurs in A-T patients (33) . To date, no effective therapy for A-T patients exists. BMT, which is already used as curative therapy for other genomic instability syndromes, could be a promising therapeutic approach (23, 29) . Therefore, the aim of this study was to investigate whether bone marrow-derived ATM-competent stem cells are able to traffic into the affected tissues and how such cell migration affects the A-T phenotype.
Our data demonstrate that the transplantation of ATMcompetent BMDCs resulted in a stable chimerism and that cells migrated into the thymus, spleen and lung, but did not cross through the BBB using a non-myeloablative host-conditioning regimen. BMT normalized the CD4 + and CD8 + lymphocyte populations, extended the lifespan and improved the growth and motor activity of Atm-deficient mice.
Our investigations confirm and extend earlier results from Bagley et al., who found an intrinsic defect in the progeny of BMDCs from Atm-deficient mice (28) . In particular, we were able to show that the number of myelopoetic and lymphopoetic progenitor cells was decreased in Atm-deficient bone marrow and that the myelopoetic and lymphopoetic progenitor cells were unable to compete with wild-type cells for bone marrow niches. This was underlined by the facts that no GFP + cells were found in the bone marrow of wild-type mice after transplantation with Atm-deficient GFP + BMDCs and that transplantation with these Atm-deficient cells had no effect on the lifespan of the wild-type mice.
Our data support previous findings that the lifespan of Atmdeficient mice transplanted with wild-type bone marrow was prolonged (28) . Interestingly, transplantation of Atm-deficient mice with Atm-deficient bone marrow cells resulted in a significantly longer lifespan when compared with untreated Atm-deficient mice. The phenomenon of sham transplantation was recently described and suggests that renewal of the stem cell niche population itself had a mild positive effect on survival (34) .
Cancer, predominantly originating from lymphoid tissues, is a major risk factor for mortality among A-T patients and has also been shown to occur at a high frequency in Atm-deficient mice (14) . In this context, it is crucial to note that BMT with ATM-positive BMDCs significantly increased the longevity of Atm-deficient mice and overcame the high tumor incidence in these animals. Other treatments, such as supplementation with antioxidants (N-acetyl-L-cysteine, EUK-189, tempol and 5--carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl) or growth hormones, have an effect on survival, but none of these completely prevent the generation of thymic lymphomas (15, 18, 35, 36) . However, in our study we sacrificed the mice at the age of 8 months, and we cannot completely rule out cancer development at later stages. In their study, Bagley et al. mainly focused on the development of thymic lymphomas, and although the median survival time was more than 60 weeks, some of the animals died of unknown causes (28) . Therefore, long-lasting studies are necessary, using a larger cohort of mice to investigate other tumors, such as colon tumors, renal tumors or hepatocellular carcinoma and to look for infiltration of T lymphoblastic lymphomas into the intestine, liver or lung (37) .
Most A-T patients suffer from some degree of immunodeficiency that results in recurrent sinopulmonary infections and progressive lung failure (31) . The latter most likely plays a role in the destruction of lung tissue. Recent studies have revealed that BMDCs contribute to lung tissue regeneration and protection and may be a promising next generation therapy for lung diseases such as chronic obstructive pulmonary disease (COPD) or severe asthma (38) . Kähler et al. have shown that bone marrow contains a number of distinct populations of progenitor cells that have been shown to contribute to lung tissue regeneration (39) . Furthermore, endothelial progenitor cells have been shown to promote angiogenesis and vasculogenesis (40) . Mesenchymal stem cells (MSCs) exhibit regenerative abilities and potent anti-inflammatory effects (41) . Therefore, an admissible hypothesis might be that lung tissue regeneration and protection against inflammation is beneficial for A-T patients.
In Atm-deficient mice, lung failure has not yet been sufficiently described, most likely because the animals die early from thymic lymphomas. Our data suggest that at least in some of the Atm-deficient mice, signs of pulmonary inflammation are present. Interestingly, our results show the engraftment of CD31 +
CD45
2 endothelial cells and EpCAM + epithelial cells into the lung tissue of transplanted Atm-deficient mice. This evidence is important for preventing at least some human respiratory abnormalities and proves that the administration of whole bone marrow leads to the migration of non-hematopoietic cells during the non-myeloablative regimen. It has been proposed that lung injury is required for stem cell engraftment. Lung injury can either be caused by induced lung damage, e.g. a myeloablative regimen using total body irradiation, smoke and acid exposure or by primary lung disease (42, 43) . The latter is most likely the cause in Atm-deficient mice as shown by our data of lung inflammation. Further experiments are needed to functionally characterize the donor-derived cells and to investigate whether the cells are transdifferentiated hematopoetic stem cells or marrow cells fused with lung cells. Overall, stem cell transplantation might be a next generation therapy for lung diseases such as COPD, and A-T might be added to the list of disorders for which BMT is useful (38) .
Another hallmark of A-T is neurodegeneration. Due to microscopic atrophy of the cerebellar cortex resulting from a reduction in Purkinje cells, granular cells and basket cells, most patients are wheelchair bound before 10 years of age (44 -46) . In this context, several studies have reported that BMDCs migrate into the brain, raising the possibility of using them as a new tool for the repair of damaged brain tissue (47, 48) . In one of the first studies, Priller et al. demonstrated the neogenesis of cerebellar Purkinje neurons derived from BDMCs in vivo (49). They found fully developed Purkinje neurons after a long-term follow-up of 15 months post BMT in chimeric C57BL/6 mice. Moreover, Alvarez-Dolado et al. showed that BMDCs may fuse in vivo with Purkinje neurons in the brain, resulting in the formation of multinucleated cells (50) .
In contrast to these investigations, we did not observe any ATM-competent or GFP + cells in the cerebellum or cerebrum of the transplanted Atm-deficient mice. One major reason could be the non-myeloablative host-conditioning regimen that we used. Although some authors have postulated that the migration of BMDCs into the CNS is possible without tissue injury or radiation, most studies confirm the use of lethal irradiation for successful BMDC migration (51) . Another explanation for the missing BMDCs migration could be the low number of MSCs in the bone marrow. As described by Alvarez-Dolado and others, in addition to neuronal stem cells, MSCs are the primary cell population directly involved in nerve cell regeneration. Furthermore, MSCs rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia (50, 52) . Thus, a low-dose radiation regime together with the transplantation of previously isolated and proliferated MSCs might comprise a successful strategy for inducing migration into the brains of Atm-deficient mice.
In the Atm-deficient mouse model (Atm tm1Awb ) we used for our investigations, only subtle alterations in the cerebellum have been observed, which are consistent with a mild decrease in their motor performance. No detectable loss of cerebellar neurons in these animals has been reported (30, 53, 54) . This lack of a detectable loss of cerebellar neurons might be because these mice do not survive long enough to exhibit degeneration. To test this hypothesis, we used MRI that allows high-resolution examination of the brains of transplanted Atmdeficient mice. MRI scans did not show any differences in 5-month-old mice, but showed a shrinking cerebellum in 8-month-old Atm-deficient mice. These results were confirmed by histologic analysis that showed abnormalities in the Purkinje cell layer in almost 50% of the animals. Our results are very interesting with respect to the study done by Li et al., which showed that the Atm tm1Awb mouse model produces a catalytically active ATM protein (ATM AWB ) that responds to DNA damage by phosphorylating p53 and Chk2 (55) . Signs of neurodegeneration in the 8-month-old Atmdeficient mice are probably because the ATM AWB protein is able to slow down damage of the Purkinje cells, but cannot totally restore the function of the wild-type protein. Thus, our data suggest that the prolonged lifespan is accompanied by neurologic changes in this mouse model of A-T, and transplantation may provide a means to investigate neurodegeneration in these mice.
Most A-T patients exhibit some deficiency in somatic growth and weight gain, starting in early childhood and leading to progressive dystrophy (13) . In addition, poor growth and weight gain is a well-characterized feature of the Atm-deficient mice, and its correction is an excellent clinical proof of general well-being and a successful BMT. Remarkably, we found that BMT significantly increased weight gain in Atm-deficient mice, raising their weights to the level of the wild-type mice. At the same time, the transplanted animals showed improved motor activity. Given that severe dystrophy and impaired weight gain affect the majority of A-T patients after puberty and at the end stage of the disease, our results are of enormous importance for counteracting the natural course of A-T.
Taken together, our results show that BMDCs migrated into the thymus, spleen and lung tissue of Atm-deficient mice, but did not cross the BBB. BMT inhibited thymic lymphomas, normalized T-lymphocyte populations and improved weight gain and rearing activity in the recipient animals. Therefore, BMT offers a new avenue leading to a possible cure for A-T. Further studies must still be done to optimize the conditioning regime and transplantation strategy.
MATERIALS AND METHODS

Animal models
In total, 25 10-week-old Atm-deficient mice (Atm tm1Awb ) (30), kindly provided by A. Wynshaw-Boris, School of Medicine, University California San Diego, were used as bone marrow recipients. To generate the donor mice, we backcrossed B5/ EGFP mice (Jackson Laboratory, ME, USA) (56) with Atmheterozygous mice and used the offspring for bone marrow reconstitution. A total of 21 Atm-deficient mice and 17 wild-type mice were included in the study as controls. All mice were housed in cages with filter tops and were fed with laboratory chow ad libitum. All animal procedures were performed according to protocols approved by the German Animal Subjects Committee (Gen.Nr.F133/09). Mice were checked weekly and sacrificed when thymic lymphomas were detectable. Weight was documented every month.
Intravenous transplantation of whole bone marrow cells
As conditioning regimen for the transplantation, the recipients received 0.125 mg/ml anti-CD4 antibody (clone GK1.5, Sigma, Steinheim, Germany) and 0.125 mg/ml anti-CD8 antibody (clone 53-6.7, Sigma) 7 days before BMT and then a second dose of each antibody, together with 200 mg/kg cyclophosphamide (80 mg/ml, Sigma), 1 day before BMT for nonmyeloablative conditioning. Bone marrow cells were sterilely harvested from GFP + donors on the day of BMT, and 6 × 10
Bone marrow cell isolation and preparation for linage marker and CFC assay
Total bone marrow was sterilely isolated from 18 weeks old GFP + wild-type, Atm-deficient or transplanted Atm-deficient mice. Cells were washed with PBS. The mononuclear cell fraction was obtained by layering the bone marrow cells on top of Histopaque 1083 (density 1.083 g/ml, Sigma, Munich, Germany) and centrifuged at 700g for 30 min.
CFC assay
To assess the number and differentiation potential of multipotential and lineage-restricted progenitors for the granulocytic and monocyte-macrophage colonies, we performed the in vitro CFC assay in methylcellulose (StemCell Technologies, Köln, Germany) according to the manufacturer's instructions. Briefly, 2 × 10 4 bone marrow mononuclear cells (BMNCs) were added to methylcellulose-based medium supplemented with hematopoietic growth factors and plated into 35 mm culture dishes in duplicates. The cells were incubated for 14 days in a humidified incubator at 378C and 5% CO 2 . On Day 14, the number of colonies and their types (CFU-GEMM, CFU-G and CFU-M) were counted using the IX71 inverted Olympus microscope (Olympus, Hamburg, Germany). To determine the differentiation capacity of the hematopoietic cells, 10 5 BMNCs were incubated 30 min at room temperature (RT) using allophycocyanin (APC)-conjugated antibodies against the following proteins: CD3e, B220 and TER119 (BD Bioscience). Following incubation, cells were washed three times in PBS and 20.000 events were analyzed on a FACSCantoII flow cytometer (Becton Dickinson, Heidelberg, Germany). The data were evaluated using Diva Software. All antibodies were purchased from Biolegend (Biolegend, Fell, Germany) unless otherwise indicated.
Immunophenotyping
Blood samples were taken at 2 weeks, 3 months and 6 months post-transplantation by tapping the vena maxillaris. Whole blood samples containing EDTA, isolated thymocytes or splenocytes were labeled with anti-CD3-PerCP, anti-CD4-PE and CD8-APC (Becton Dickinson) and analyzed for GFP expression. Bone marrow cells were stained with anti-CD3e-PE, anti-CD45B220-PerCP or anti-Ter119-APC. After staining, erythrocytes were lyzed with FACS-lyzing solution (Becton Dickinson, Qume Drive, San Jose, CA, USA), washed with PBS and fixed with 1% paraformaldehyde. Then, 10.000 events were analyzed on a FACSCalibur flow cytometer (Becton Dickinson). The data were evaluated using Cellquest software. 
Sorting and genotyping of GFP
Western blot analysis
Splenocytes were isolated from Atm-deficient mice, wild-type mice and Atm-deficient mice 10 weeks after transplantation. For immunoblotting of phospho-p53 (Ser15) mice spleens were homogenized using the Precellys 24 homogenizer (Peqlab Biotechnologie GmbH, Erlangen, Germany). Afterwards, proteins were precipitated with ice-cold 10% TCA/ acetone and centrifuged at 14,000 g for 5 min. The resulting pellet was dissolved in 20 mM potassium-phosphate buffer with 1% SDS. 10 mg denaturated proteins were separated on SDS gels (4-12% RunBlue SDS-PAGE Precast Gel, Expedeon, Harston, UK) according to the manufactureŕs protocol. After separation the proteins were blotted on a PVDF membrane (Merck Millipore Immobilon P (0,45 mm), Darmstadt, Germany), which was blocked using RotiBlock (Roth, Karlsruhe, Germany) overnight at 48C. After washing three times with TBS-T the membrane was probed with the anti-phosphop53 Ser15 antibody (Calbiochem, Merck Millipore, Darmstadt, Germany). For visualization the membrane was incubated with SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific, Waltham, USA). Images were acquired using the VersaDoc TM MP4000 Imaging System (BioRad, Munich, Germany). The immunopositive bands were analyzed with the ImageLab software (BioRad, Munich, Germany). Actin was used as a loading control (anti-actin, Sigma-Aldrich, Hamburg, Germany).
Isolation of lung cells
Lungs were harvested and single cells suspensions were generated using a Lung Dissociation Kit (Miltenyi, Bergisch Gladbach, Germany) and the gentleMACS Dissociator (Miltenyi) according to the manufacturer's instructions. The single-cell suspensions were stained with CD31-APC (Biolegend) and CD326-PE-Cy7 (Biolegend) and analyzed on a FACSCantoII flow cytometer (Becton Dickinson). The data were evaluated using Diva Software.
Histone H2AX phosphorylation
Wild-type and Atm-deficient mice positive for GFP and transplanted Atm-deficient mice were mock-irradiated or irradiated with 2 Gy in vivo at the age of 18-20 weeks. Animals were directly sacrificed, and cells were isolated from bone marrow 3 h and 24 h after irradiation. 1 × 10 6 cells were fixed with fixation buffer for 10 min at RT (BD Cytofix, BD Pharmingen, San Diego, CA, USA), washed with PBS and permeabilized with -208C cold Perm III buffer (BD Phosflow Perm III buffer) for 5 min at RT. Cells were washed with PBS and blocked with 3% fetal calf serum in PBS for 30 min at RT.
The anti-H2AX(S139) antibody [Alexa Fluor 647 Mouse anti-H2AX(pSer139), BD Pharmingen] was added (1:10) and incubated for 60 min at RT in the dark. After washing the cells three times with PBS, the nuclei were counterstained with Hoechst33342 (5 mg/ml, green pseudocolor) before analyzing the cells with FACS CantoII. The data were evaluated using Diva Software.
Immunohistochemistry
Tissue was harvested 6 months post-transplantation. Mice were anesthetized with an intraperitoneal Ketamin -Rompun mixture (20% Ketamin, CuraMED GmbH, Karlsruhe, Germany; 8% Rompun, Bayer Vital GmbH, Leverkusen, Germany) injection. They were perfused transcardially with 4% paraformaldehyde in PBS. From the brain tissue, 40 mm-thick serial sections were cut with a vibratome. In addition, 16 mm cryosections were obtained from the lungs. For immunohistochemistry, the brain sections were incubated in PBS with 10% normal goat serum and 0.5% Triton X-100. The primary antibody was added overnight with a 1:2000 dilution of anticalbindin-D28K (mouse monoclonal; Sigma). Alexa568-conjugated secondary antibody (goat antimouse, Invitrogen) was added at a 1:250 dilution for 1 h. Omission of primary antibodies served as a negative control and resulted in no detectable staining. Digital micrographs of GFP and Alexa568 fluorescence were obtained on a conventional fluorescence microscope (CKX 41, Olympus, Hamburg, Germany) equipped with a camera (Retiga 2000R Fast 1394, Q-Imaging, Surrey, Canada). Additionally, lungs were stained with anti-CD45 (purified rat antimouse antibody, BD Pharmingen) as a primary antibody for 60 min at RT at a dilution of 1:50 and Alexa568-conjugated secondary antibody (donkey antimouse IgG antibody, Invitrogen) at a dilution of 1:500 at RT and covered with DAPI fluorescence mounting medium (Dako, Hamburg, Germany) to evaluate the relation of CD45 to GFP using a conventional fluorescent microscope.
Naphtol AS-D chloroacetate esterase stain was used to detect the accumulation of activated neutrophils in 5 mm cryostat liver sections and was assessed by staining for chloroacetate esterase, a neutrophil-specific marker (Naphthol ASD-chloroacetate esterase kit, Sigma-Aldrich).
Locomotoric behavior
Rotarod testing (rod diameter 30 mm) was performed on a UGO Basile accelerating Rotarod for mice (model 7650, Stoelting, Woodvale, IL, USA). On four consecutive days, mice were given training trials with the rotarod adjusted to accelerate from 6 to 40 rpm. Afterward, the mice were tested using the same conditions with accelerating speed for a 700 s test period.
Open field
Plexiglass cages with white floors and translucent walls were used as open fields (26 × 26 × 39 cm; Truscan, Coulbourn Instruments, Allentown, PA, USA). Behavioral activity was measured using infrared beams. The patterns of two layers of beam breaks were computed (Truscan Software) to obtain parameters of locomotion and rearing. Each animal was tested for 5 min at 6 months post-transplantation.
Magnetic resonance imaging
MRI scans were performed at the Max Planck Institute in Bad Nauheim. These scans involved different age groups: four Atm-knockout mice 3 months post-transplantation, three Atm-knockout 6 months post-transplant and three wild-type and Atm-knockout mice at each age. MRI measurements were performed on a 7.0 T Bruker Pharmascan, equipped with a 300 mT/m gradient system, using a custom-built circularly polarized birdcage resonator (Bruker, Ettlingen, Germany). The 3 and 6 months old mice (x untreated, y treated) were measured under volatile isoflurane (1.2%) anesthesia, monitored for breathing rate and temperature was maintained at 378C with a heated water system. In the PD-and T 2 -weighted spin echo images, a multislice-multiecho sequence was used: echo time ¼ 24.6 ms; repetition time ¼ 3000 ms; field of view ¼ 2.50 × 2.24 cm 2 ; matrix size ¼ 512 × 256; slice thickness ¼ 0.50 mm; slice orientation ¼ coronal.
To compare the size of the cerebellum and cerebrum at various times, the relationship between the widths of the encephalic section and cranial interior was determined. The data were evaluated using Adobe Photoshop Elements 4.0.
Statistics
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). Values are presented as mean (+SEM) and were analyzed using MannWhitney U-test or Wilcoxon -Mann -Whitney test. For multiple comparisons, we used Kruskal -Wallis testing. The survival times of the mice were used to generate Kaplan -Meier survival curves that were compared using the log-rank (Mantel -Cox) test, and the survival times of the mice were compared using Scheffe's F protected least-significant difference test. The following symbols indicate significant P-values: * P , 0.05, * * P , 0.01 and * * * P , 0.001.
